Search
Close this search box.

The Role of Disc Nutrition in the Etiology and Clinical Treatment of Disc Degeneration

Studies

Study First Submitted Date 2019-10-18
Study First Posted Date 2019-10-22
Last Update Posted Date 2023-04-18
Start Month Year May 2, 2024
Primary Completion Month Year February 3, 2026
Verification Month Year April 2023
Verification Date 2023-04-30
Last Update Posted Date 2023-04-18

Detailed Descriptions

Sequence: 20764909
Description Low back pain, which is frequently associated with intervertebral disc degeneration, is the most common cause of adult disability in the United States. Among active service members, the incidence of disc degeneration more than doubled from 2001 to 2010, with over 68,000 days of lost duty time attributed to disc degeneration.2 The most common location of chronic pain in Veterans is the spine. The incidence of back pain in the general public has remained relatively stable over the past decade, however, there has been more than a 50% increase in the number of Veterans diagnosed with back pain. The intervertebral discs are the largest avascular structures in the body, and therefore cells within the disc rely on transport from the small vessels in the adjacent vertebral endplate to receive nutrients and expel waste products. Despite the immense social and economic burden of back pain, the etiology of disc degeneration remains poorly understood. Because of the avascular nature of the disc, it has been speculated that poor disc nutrition characterized by reduced trans-endplate transport into the disc could contribute to the initiation and progression of degeneration. If a reduction in trans-endplate transport of nutrients and waste products is a primary contributor to the initiation and progression of the degenerative cascade, then enhancing disc nutrition may have a therapeutic effect. Physical therapy and exercise can be very effective in managing back pain for certain patients, yet it is not fully understood why certain patients respond to physical therapy and others do not, and what effects such interventions have on disc nutrition and disc health. The goal of this study is to undertake a pilot study to determine the feasibility and preliminary outcomes of utilizing quantitative MRI in human patients to quantify changes in disc health and trans-endplate transport over the course of physical therapy.

To do so, patients with low back pain and concomitant disc degeneration, who have not had prior spinal surgery, will be recruited. Recruited patients will undergo MRI T2-mapping and post-contrast enhanced T1-mapping of their lumbar spines at 1.5T to measure disc health and nutrition, respectively. Patients will then begin a 6 week physical therapy treatment regimen, after which the same MRI scans will be performed again on each patient. Pain and disability level of patients will be assessed via the visual analog scale (VAS) and Oswestry Disability Index (ODI) questionnaires, both pre- and post-treatment. Lumbar active range of motion will also be quantified at the initial and final in-office physical therapy session. Inclinometers will be placed at the thoracolumbar junction and sacrum, and the patient asked to bend forward and backward. Lumbar flexion will be quantified as the difference in motion between the two inclinometers.

Significant differences T1 and T2 values in the disc, as well as VAS and ODI scores and lumbar range of motion, before and after physical therapy will be assessed via a paired t-test, with significance defined as p<0.05. Univariate linear correlations between the changes in T1 or T2 values and changes in VAS, ODI scores and lumbar range of motion will be performed to determine if altered disc health or nutrition with physical therapy is significantly correlated with improvements in pain and disability.

Facilities

Sequence: 200473859
Name Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
City Philadelphia
State Pennsylvania
Zip 19104-4551
Country United States

Facility Contacts

Sequence: 28160860
Facility Id 200473859
Contact Type primary
Name Sarah E Gullbrand, PhD
Email sgullb@pennmedicine.upenn.edu
Phone 215-823-5800

Facility Investigators

Sequence: 18363073
Facility Id 200473859
Role Principal Investigator
Name Sarah E. Gullbrand, PhD

Conditions

Sequence: 52282452 Sequence: 52282453
Name Back Pain Name Intervertebral Disc Degeneration
Downcase Name back pain Downcase Name intervertebral disc degeneration

Id Information

Sequence: 40238961
Id Source org_study_id
Id Value B3118-W

Countries

Sequence: 42657121
Name United States
Removed False

Design Groups

Sequence: 55717395
Group Type Experimental
Title Physical therapy
Description Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.

Interventions

Sequence: 52594569
Intervention Type Procedure
Name Physical Therapy
Description Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.

Keywords

Sequence: 80025895 Sequence: 80025896 Sequence: 80025897 Sequence: 80025898
Name spine Name intervertebral disc Name physical therapy Name imaging
Downcase Name spine Downcase Name intervertebral disc Downcase Name physical therapy Downcase Name imaging

Design Outcomes

Sequence: 177788544 Sequence: 177788545 Sequence: 177788548 Sequence: 177788546 Sequence: 177788547
Outcome Type primary Outcome Type primary Outcome Type primary Outcome Type primary Outcome Type primary
Measure Change in Disc T2 relaxation time Measure Change in Visual Analog Scale (VAS) score Measure Change in Oswestry Disability Index (ODI) score Measure Change in Lumbar Range of Motion Measure Change in Disc T1 relaxation time
Time Frame 0 to 6 weeks Time Frame 0 to 6 weeks Time Frame 0 to 6 weeks Time Frame 0 to 6 weeks Time Frame 0 to 6 weeks
Description Subjects will undergo MRI scanning to obtain T2-maps of the lumbar spine before and after 6 weeks of physical therapy. T2 relaxation times of the disc tissues are calculated from the images. Description Subjects will complete a visual analog scale (VAS) for their back pain before and after 6 weeks of physical therapy. This is a scale from 0 (no pain) to 15 (the worst imaginable pain). Description Subjects will complete the ODI questionnaire before and after 6 weeks of physical therapy. This is a scale from 0 (no disability) to 50 (bed bound). Description Lumbar range of motion will be measured using inclinometers placed on the subject’s upper and lower back, at both the index and final in-office physical therapy visit. Description Subjects will undergo MRI scanning to obtain post-contrast enhanced T1 maps of the lumbar spine before and after 6 weeks of physical therapy. To obtain the T1 maps, an intravenous catheter will be placed, and 0.1 mmols/kg of Omniscan will be administered. T1 MRIs will be acquired prior to and 2 hours following Omniscan administration. T1 relaxation times of the disc tissues are calculated from the images.

Browse Conditions

Sequence: 193912266 Sequence: 193912267 Sequence: 193912268 Sequence: 193912269
Mesh Term Intervertebral Disc Degeneration Mesh Term Spinal Diseases Mesh Term Bone Diseases Mesh Term Musculoskeletal Diseases
Downcase Mesh Term intervertebral disc degeneration Downcase Mesh Term spinal diseases Downcase Mesh Term bone diseases Downcase Mesh Term musculoskeletal diseases
Mesh Type mesh-list Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor

Sponsors

Sequence: 48423331
Agency Class FED
Lead Or Collaborator lead
Name VA Office of Research and Development

Overall Officials

Sequence: 29345332
Role Principal Investigator
Name Sarah E. Gullbrand, PhD
Affiliation Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

Central Contacts

Sequence: 12035852
Contact Type primary
Name Sarah E Gullbrand, PhD
Phone (215) 823-5800
Email sgullb@pennmedicine.upenn.edu
Role Contact

Design Group Interventions

Sequence: 68299298
Design Group Id 55717395
Intervention Id 52594569

Eligibilities

Sequence: 30829985
Gender All
Minimum Age 30 Years
Maximum Age 70 Years
Healthy Volunteers Accepts Healthy Volunteers
Criteria Inclusion Criteria:

Current activity limiting low back pain
With symptoms of any duration
With or without symptoms extending distal to the buttocks
Medically stable
Candidate for physical therapy

Exclusion Criteria:

Documented history of prior spinal surgery

Contraindications to MRI including:

claustrophobia
pregnancy

implanted electronic devices

pacemakers, cochlear implant, insulin pumps, etc

metallic foreign bodies

i.e. shrapnel

documented history of contraindications to gadodiamide (Omniscan) administration:

chronic severe kidney disease
acute kidney injury
impaired elimination of gadolinium based contrast agents
pre-existing renal insufficiency
a prior hypersensitivity reaction to MRI contrast

Adult True
Child False
Older Adult True

Calculated Values

Sequence: 254131482
Number Of Facilities 1
Registered In Calendar Year 2019
Were Results Reported False
Has Us Facility True
Has Single Facility True
Minimum Age Num 30
Maximum Age Num 70
Minimum Age Unit Years
Maximum Age Unit Years
Number Of Primary Outcomes To Measure 5

Designs

Sequence: 30575907
Allocation N/A
Intervention Model Single Group Assignment
Observational Model
Primary Purpose Basic Science
Time Perspective
Masking None (Open Label)

Responsible Parties

Sequence: 28942315
Responsible Party Type Sponsor